Osteoarthritis gene therapy in 2022
- 9 November 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 35 (1) , 37-43
Abstract
Purpose of review: To assess the present status of gene therapy for osteoarthritis (OA). Recent findings: An expanding list of cDNAs show therapeutic activity when introduced into the joints of animals with experimental models of OA. In vivo delivery with adenovirus or adeno-associated virus is most commonly used for this purpose. The list of encoded products includes cytokines, cytokine antagonists, enzymes, enzyme inhibitors, growth factors and noncoding RNA. Elements of CRISPR-Cas have also been delivered to mouse knees to ablate key genes. Several human trials have been initiated, using transgenes encoding transforming growth factor-β1, interleukin-1 receptor antagonist, interferon-β, the NKX3.2 transcription factor or variant interleukin-10. The first of these, using ex vivo delivery with allogeneic chondrocytes, gained approval in Korea which was subsequently retracted. However, it is undergoing Phase III clinical trials in the United States. The other trials are in Phase I or II. No gene therapy for OA has current marketing approval in any jurisdiction. Summary: Extensive preclinical data support the use of intra-articular gene therapy for treating OA. Translation is beginning to accelerate and six gene therapeutics are in clinical trials. Importantly, venture capital has begun to flow and at least seven companies are developing products. Significant progress in the future can be expected.Keywords
This publication has 45 references indexed in Scilit:
- Lentiviral Small Hairpin RNA Knockdown of Macrophage Inflammatory Protein-1γ Ameliorates Experimentally Induced Osteoarthritis in MiceHuman Gene Therapy, 2013
- Proteoglycan 4 Expression Protects Against the Development of OsteoarthritisScience Translational Medicine, 2013
- Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stressOsteoarthritis and Cartilage, 2013
- Intraarticular gene transfer of thrombospondin‐1 suppresses the disease progression of experimental osteoarthritisJournal of Orthopaedic Research, 2010
- Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle‐derived stem cells expressing bone morphogenetic protein 4 and soluble flt‐1Arthritis & Rheumatism, 2009
- Adenovirus-Mediated Kallistatin Gene Transfer Ameliorates Disease Progression in a Rat Model of Osteoarthritis Induced by Anterior Cruciate Ligament TransectionHuman Gene Therapy, 2009
- Risk factors for osteoarthritis: geneticsOsteoarthritis and Cartilage, 2004
- Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist geneGene Therapy, 2002
- In Vivo Transfer of Interleukin-1 Receptor Antagonist Gene in Osteoarthritic Rabbit Knee JointsThe American Journal of Pathology, 1999
- In vivo suppression of early experimental osteoarthritis by interleukin‐1 receptor antagonist using gene therapyArthritis & Rheumatism, 1997